Monopar Therapeutics (MNPR) Income towards Parent Company (2017 - 2020)
Monopar Therapeutics (MNPR) has disclosed Income towards Parent Company for 4 consecutive years, with -$2.3 million as the latest value for Q4 2020.
- Quarterly Income towards Parent Company fell 84.57% to -$2.3 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was -$6.5 million through Dec 2020, down 50.54% year-over-year, with the annual reading at -$15.6 million for FY2024, 85.94% down from the prior year.
- Income towards Parent Company hit -$2.3 million in Q4 2020 for Monopar Therapeutics, down from -$1.6 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$373839.0 in Q1 2017 to a low of -$14.9 million in Q3 2017.
- Historically, Income towards Parent Company has averaged -$1.9 million across 4 years, with a median of -$929233.5 in 2018.
- Biggest YoY gain for Income towards Parent Company was 95.52% in 2018; the steepest drop was 140.01% in 2018.
- Year by year, Income towards Parent Company stood at -$736800.0 in 2017, then decreased by 25.73% to -$926358.0 in 2018, then tumbled by 32.23% to -$1.2 million in 2019, then tumbled by 84.57% to -$2.3 million in 2020.
- Business Quant data shows Income towards Parent Company for MNPR at -$2.3 million in Q4 2020, -$1.6 million in Q3 2020, and -$1.5 million in Q2 2020.